Cargando…

Neoadjuvant chemotherapy remodels the tumor immune microenvironment by increasing activated and cytotoxic T cell, decreasing B cells and macrophages in small cell lung cancer

Detalles Bibliográficos
Autores principales:	Shang, Xiaoling, Zhang, Chenyue, Wang, Kai, Wang, Haiyong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10512529/ https://www.ncbi.nlm.nih.gov/pubmed/37735693 http://dx.doi.org/10.1186/s12967-023-04526-4

Ejemplares similares

Intratumor heterogeneity is associated with less CD8(+) T cell infiltration and worse survival in patients with small cell lung cancer
por: Zhang, Chenyue, et al.
Publicado: (2022)

Surgery as a Potential Treatment Option for Patients With Stage III Small-Cell Lung Cancer: A Propensity Score Matching Analysis
por: Zhang, Chenyue, et al.
Publicado: (2019)

Orchestrating smart therapeutics to achieve optimal treatment in small cell lung cancer: recent progress and future directions
por: Zhang, Chenyue, et al.
Publicado: (2023)

Genetic alternations and immune characteristics in patients with small cell lung cancer
por: Zhang, Chenyue, et al.
Publicado: (2021)

Tumor microenvironment remodeling after neoadjuvant immunotherapy in non-small cell lung cancer revealed by single-cell RNA sequencing
por: Hu, Junjie, et al.
Publicado: (2023)

A 5-Gene Signature Is Closely Related to Tumor Immune Microenvironment and Predicts the Prognosis of Patients with Non-Small Cell Lung Cancer
por: Li, Jia, et al.
Publicado: (2020)

Molecular subtyping of small‐cell lung cancer based on mutational signatures with different genomic features and therapeutic strategies
por: Wang, Haiyong, et al.
Publicado: (2022)

Single-cell profiling of immune cells after neoadjuvant pembrolizumab and chemotherapy in IIIA non-small cell lung cancer (NSCLC)
por: Hui, Zhenzhen, et al.
Publicado: (2022)

Tumor microenvironment features decipher the outperformance of neoadjuvant immunochemotherapy over chemotherapy in resectable non-small cell lung cancer
por: Cai, Wenhan, et al.
Publicado: (2022)

Reconstruction of the gastric cancer microenvironment after neoadjuvant chemotherapy by longitudinal single-cell sequencing
por: Chen, Yingtai, et al.
Publicado: (2022)

Better cancer specific survival in young small cell lung cancer patients especially with AJCC stage III
por: Wang, Haiyong, et al.
Publicado: (2017)

Effect of neoadjuvant chemotherapy on the immune microenvironment in non–small cell lung carcinomas as determined by multiplex immunofluorescence and image analysis approaches
por: Parra, Edwin R., et al.
Publicado: (2018)

Reprograming the tumor immunologic microenvironment using neoadjuvant chemotherapy in osteosarcoma
por: Deng, Chuangzhong, et al.
Publicado: (2020)

Novel Cytotoxic Chemotherapies in Small Cell Lung Carcinoma
por: Cortinovis, Diego, et al.
Publicado: (2021)

The breast cancer immune microenvironment is modified by neoadjuvant chemotherapy
por: Urueña, Claudia, et al.
Publicado: (2022)

The effect of neoadjuvant chemotherapy on the tumor immune microenvironment in gastrointestinal tumors
por: Wang, Yujie, et al.
Publicado: (2022)

CD44, a marker of cancer stem cells, is positively correlated with PD-L1 expression and immune cells infiltration in lung adenocarcinoma
por: Zhang, Chenyue, et al.
Publicado: (2020)

TERT mutations correlate with higher TMB value and unique tumor microenvironment and may be a potential biomarker for anti‐CTLA4 treatment
por: Li, Huahua, et al.
Publicado: (2020)

Dendritic Cell Vaccination in Non-Small Cell Lung Cancer: Remodeling the Tumor Immune Microenvironment
por: Abascal, Jensen, et al.
Publicado: (2023)

Increased Cystatin F Levels Correlate with Decreased Cytotoxicity of Cytotoxic T Cells
por: Prunk, Mateja, et al.
Publicado: (2019)

Tumor immune microenvironment predicts the pathologic response of neoadjuvant chemoimmunotherapy in non–small‐cell lung cancer
por: Han, Rui, et al.
Publicado: (2023)

Loss of heterozygosity related to TMB and TNB may predict PFS for patients with SCLC received the first line setting
por: Zhang, Chenyue, et al.
Publicado: (2021)

Clinicopathological Difference and Survival Impact of Patients with c-SCLC and SCLC
por: Zhang, Chenyue, et al.
Publicado: (2021)

Small Cell Neuroendocrine Carcinoma of the Urinary Tract Successfully Managed with Neoadjuvant Chemotherapy
por: Ahsaini, Mustapha, et al.
Publicado: (2013)

Neoadjuvant PD‐1 inhibitor combines with chemotherapy versus neoadjuvant chemotherapy in resectable squamous cell carcinoma of the lung
por: Feng, Yuan, et al.
Publicado: (2021)

Neoadjuvant Chemotherapy Improves the Immunosuppressive Microenvironment of Bladder Cancer and Increases the Sensitivity to Immune Checkpoint Blockade
por: Luo, Hao, et al.
Publicado: (2022)

Neoadjuvant immunotherapy combined with chemotherapy significantly improved patients’ overall survival when compared with neoadjuvant chemotherapy in non-small cell lung cancer: A cohort study
por: Dai, Fuqiang, et al.
Publicado: (2022)

Aneuploid Circulating Tumor Cells as a Predictor of Response to Neoadjuvant Chemotherapy in Non-Small Cell Lung Cancer
por: Huang, Miao, et al.
Publicado: (2021)

Neoadjuvant immunotherapy and neoadjuvant chemotherapy in resectable non-small cell lung cancer: A systematic review and single-arm meta-analysis
por: Wang, He, et al.
Publicado: (2022)

Effect of neoadjuvant chemotherapy on the immune microenvironment in gastric cancer as determined by multiplex immunofluorescence and T cell receptor repertoire analysis
por: Xing, Xiaofang, et al.
Publicado: (2022)

Successful Neoadjuvant Chemotherapy for Small-Cell Neuroendocrine Carcinoma of the Pancreas: A Case Report
por: Li, Keyu, et al.
Publicado: (2021)

Role of Neoadjuvant Chemotherapy in Non-small Cell Lung Cancer in the COVID-19 Pandemic
por: Karaman, Elanur, et al.
Publicado: (2022)

Neoadjuvant immunochemotherapy with pembrolizumab plus chemotherapy in resectable non-small cell lung cancer
por: Chen, Yulong, et al.
Publicado: (2023)

Identification of a Gene Signature Closely Related to Immunosuppressive Tumour Microenvironment Predicting Prognosis of Patients in EGFR Mutant Lung Adenocarcinoma
por: Li, Jia, et al.
Publicado: (2021)

Peripheral T cell cytotoxicity predicts T cell function in the tumor microenvironment
por: Iwahori, Kota, et al.
Publicado: (2019)

MDSC-decreasing chemotherapy increases the efficacy of cytokine-induced killer cell immunotherapy in metastatic renal cell carcinoma and pancreatic cancer
por: Wang, Zibing, et al.
Publicado: (2015)

Therapeutic utility of Lung-MAP: ushering into an era of genomic and biomarker-driven clinical trials
por: Zhang, Chenyue, et al.
Publicado: (2021)

Neoadjuvant Gene-Mediated Cytotoxic Immunotherapy for Non-Small-Cell Lung Cancer: Safety and Immunologic Activity
por: Predina, Jarrod D., et al.
Publicado: (2021)

Safety and Feasibility of Esophagectomy Following Neoadjuvant Immunotherapy Combined with Chemotherapy for Esophageal Squamous Cell Carcinoma
por: Gu, Yi-Min, et al.
Publicado: (2022)

Feasibility of double sleeve lobectomy after neoadjuvant chemotherapy in patients with non-small-cell lung cancer
por: Bao, Yi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_87o8thfklvchcootk6f060cm29